GSK's Ris-Rez achieves 61% response rate at 8 mg/kg in early-stage lung cancer trial
GSK•GSK said investigational Ris-Rez achieved a 61% response rate at 8 mg/kg in a Phase Ib trial for relapsed extensive-stage small cell lung cancer, with a manageable safety profile. The findings supported selecting the higher dose for an ongoing Phase III trial.
1. Phase Ib findings
GSK reported positive antitumor activity and a manageable safety profile for investigational Ris-Rez in relapsed extensive-stage small cell lung cancer, with a 61% response rate at 8 mg/kg. The findings supported selection of the higher dose for the ongoing global Phase III EMBOLD SCLC-301 trial. Results will be presented at the European Society for Medical Oncology Congress 2026 in Madrid.
